Technology ID
TAB-3601
Development of a Therapy for the Treatment of Zellweger Spectrum Disorder
E-Numbers
E-230-2016-0
Lead Inventor
Inglese, James (NCATS)
Co-Inventors
Dranchak, Patricia (NCATS)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Neurology
Lead IC
NCATS
ICs
NCATS
This technology includes a method for selecting a therapeutic effective amount of one of two compounds (including naltriben and naltrin) for the treatment of Zellweger Spectrum Disorder (ZSD), or any disease associated with peroxisome dysfunction. The compounds were identified using a cell-image based high-content screening (HCS) assay to identify small molecules that enhance peroxisome assembly in immortalized skin fibroblasts obtained from a ZSD patient.
Commercial Applications
Clinical work with the identified compounds may result in the establishment of new therapeutic agents effective for Zellweger Spectrum Disorder.
Competitive Advantages
Current treatment options are palliative in nature and there is a need to develop targeted therapies that address the peroxisome assembly defects responsible for disease development and progression.
Licensing Contact: